(Press Release) MabGenesis and Kyoritsu Seiyaku Corporation announce collaborations to discover and develop novel monoclonal antibodies in canine

Mabgenesis and Kyoritsu Seiyaku Corporation headquartered in Tokyo, a global leader in animal health, announce that they have entered into collaborations to discover and develop novel therapeutic monoclonal antibodies for canine. Please see the joint press release in Japanese here.